Zaniboni Alberto
Alberto Zaniboni, Medical Oncology Unit, Fondazione Poliambulanza, 25124 Brescia, Italy.
World J Gastrointest Surg. 2015 Dec 27;7(12):356-9. doi: 10.4240/wjgs.v7.i12.356.
Newer active drugs have been recently added to the pharmacological armamentarium for the treatment of metastatic colorectal cancer. Aflibercept, a recombinant fusion protein composed of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) 1 and 2 and the Fc portion of human immunoglobulin G1 (IgG1), is an attractive second-line option in combination with folfiri for patients who have failed folfox +/- bevacizumab. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGFR-2, provided similar results in the same setting. Tas-102, an oral fluoropyrimidine, and regorafenib, a multi-tyrosine kinase inhibitor, are both able to control the disease in a considerable proportion of patients when all other available treatments have failed. These new therapeutic options along with the emerging concept that previous therapies may also be reitroduced or rechallenged after regorafenib and Tas-102 failure are bringing new hope for thousands of patients and their families.
最近，治疗转移性结直肠癌的药物库中新增了一些新型活性药物。阿柏西普是一种重组融合蛋白，由人血管内皮生长因子受体（VEGFR）1和2的细胞外结构域以及人免疫球蛋白G1（IgG1）的Fc部分组成，对于接受过FOLFOX±贝伐单抗治疗失败的患者，它是一种有吸引力的二线联合FOLFIRI治疗选择。雷莫西尤单抗是一种靶向VEGFR-2的人IgG1单克隆抗体，在相同情况下也能产生相似的效果。TAS-102是一种口服氟嘧啶，瑞戈非尼是一种多酪氨酸激酶抑制剂，当所有其他可用治疗均失败时，二者均能在相当一部分患者中控制疾病。这些新的治疗选择，以及在瑞戈非尼和TAS-102治疗失败后，之前的治疗方法也可能重新引入或再次使用这一新兴概念，正在给成千上万的患者及其家庭带来新的希望。
